CbdMD Competitors
| YCBD Stock | USD 0.87 0.17 16.35% |
CbdMD vs Flora Growth Correlation
Significant diversification
The correlation between cbdMD Inc and FLGC is 0.02 (i.e., Significant diversification) for selected investment horizon. Overlapping area represents the amount of risk that can be diversified away by holding cbdMD Inc and FLGC in the same portfolio, assuming nothing else is changed.
Moving against CbdMD Stock
| 0.46 | ALTS | ALT5 Sigma | PairCorr |
| 0.44 | KALA | Kala Pharmaceuticals | PairCorr |
| 0.38 | PIFMY | Indofood Sukses Makmur | PairCorr |
| 0.34 | SNY | Sanofi ADR | PairCorr |
CbdMD Competition Correlation Matrix
Typically, diversification allows investors to combine positions across different asset classes to reduce overall portfolio risk. Correlation between CbdMD and its competitors represents the degree of relationship between the price movements of corresponding stocks. A correlation of about +1.0 implies that the price of CbdMD and its corresponding peer move in tandem. A correlation of -1.0 means that prices move in opposite directions. A correlation of close to zero suggests that the price movements of assets are uncorrelated; in other words, the historical price movement of cbdMD Inc does not affect the price movement of the other competitor.
High positive correlations
| High negative correlations
|
Risk-Adjusted Indicators
There is a big difference between CbdMD Stock performing well and CbdMD Company doing well as a business compared to the competition. There are so many exceptions to the norm that investors cannot definitively determine what's good or bad unless they analyze CbdMD's multiple risk-adjusted performance indicators across the competitive landscape. These indicators are quantitative in nature and help investors forecast volatility and risk-adjusted expected returns across various positions.| Mean Deviation | Jensen Alpha | Sortino Ratio | Treynor Ratio | Semi Deviation | Expected Shortfall | Potential Upside | Value @Risk | Maximum Drawdown | ||
|---|---|---|---|---|---|---|---|---|---|---|
| BFRI | 3.53 | (0.21) | 0.00 | (0.03) | 0.00 | 6.76 | 34.13 | |||
| EVOK | 8.07 | 3.76 | 0.92 | 9.72 | 1.89 | 9.34 | 141.75 | |||
| SBFM | 2.22 | (0.72) | 0.00 | (0.97) | 0.00 | 4.13 | 13.93 | |||
| SNOA | 2.12 | (0.29) | 0.00 | (0.53) | 0.00 | 5.03 | 19.00 | |||
| MHUA | 8.36 | (0.12) | 0.00 | 0.10 | 0.00 | 27.69 | 60.20 | |||
| NRSN | 4.49 | (0.08) | 0.00 | 16.19 | 0.00 | 12.82 | 34.62 | |||
| SSKN | 3.35 | (0.62) | 0.00 | (0.30) | 0.00 | 7.35 | 18.68 | |||
| GBS | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||
| CDIO | 5.19 | (1.26) | 0.00 | (0.82) | 0.00 | 8.44 | 38.04 | |||
| FLGC | 5.71 | (0.07) | 0.00 | 0.07 | 0.00 | 9.42 | 30.99 |
Cross Equities Net Income Analysis
Compare cbdMD Inc and related stocks such as Biofrontera, Evoke Pharma, and Sunshine Biopharma Net Income Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| BFRI | (11 M) | (11 M) | (11 M) | (11 M) | (11 M) | (11 M) | (11 M) | (11 M) | (11 M) | (11 M) | (11 M) | (37.7 M) | (640 K) | (20.1 M) | (17.8 M) | (16 M) | (16.8 M) |
| EVOK | (2.4 M) | (2.4 M) | (2 M) | (2.8 M) | (13.2 M) | (12.1 M) | (10.7 M) | (12.2 M) | (7.6 M) | (7.1 M) | (13.2 M) | (8.5 M) | (8.2 M) | (7.8 M) | (5.4 M) | (4.8 M) | (5.1 M) |
| SBFM | (13.1 K) | (556.2 K) | (708 K) | (2.5 M) | (1.9 M) | (1.7 M) | (3.5 M) | (1 M) | (2.2 M) | (1.7 M) | (2.8 M) | (12.4 M) | (26.7 M) | (4.5 M) | (5.1 M) | (4.6 M) | (4.9 M) |
| SNOA | (167 K) | (7.3 M) | (5.4 M) | 3.7 M | (8.2 M) | (10.2 M) | 9.3 M | (14.3 M) | (11.8 M) | (3.3 M) | (4 M) | (5.1 M) | (5.2 M) | (4.8 M) | (3.5 M) | (4 M) | (4.2 M) |
| MHUA | 15.5 M | 15.5 M | 15.5 M | 15.5 M | 15.5 M | 15.5 M | 15.5 M | 15.5 M | 15.5 M | 15.4 M | 19 M | 20 M | 6.2 M | 11.6 M | 10.8 M | 9.8 M | 11.3 M |
| NRSN | (1.2 M) | (1.2 M) | (1.2 M) | (1.2 M) | (1.2 M) | (1.2 M) | (1.2 M) | (1.2 M) | (1.2 M) | (1.2 M) | (2.8 M) | (4 M) | (12.3 M) | (10.1 M) | (10.2 M) | (9.2 M) | (9.6 M) |
| SSKN | (2.3 M) | (20.4 M) | (22.7 M) | (25.9 M) | (16 M) | (27.9 M) | (3.3 M) | (21.5 M) | (4 M) | (3.8 M) | (4.4 M) | (2.7 M) | (5.5 M) | (10.8 M) | (10.1 M) | (9.1 M) | (9.5 M) |
| CDIO | (605.2 K) | (605.2 K) | (605.2 K) | (605.2 K) | (605.2 K) | (605.2 K) | (605.2 K) | (605.2 K) | (605.2 K) | (605.2 K) | (605.2 K) | (620.4 K) | (4.7 M) | (8.4 M) | (8.4 M) | (7.5 M) | (7.2 M) |
cbdMD Inc and related stocks such as Biofrontera, Evoke Pharma, and Sunshine Biopharma Net Income description
Net income is one of the most important fundamental items in finance. It plays a large role in cbdMD Inc financial statement analysis. It represents the amount of money remaining after all of cbdMD Inc operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue.CbdMD Competitive Analysis
The better you understand CbdMD competitors, the better chance you have of utilizing it as a position in your portfolios. From an individual investor's perspective, CbdMD's competitive analysis can cover a whole range of metrics. Some of these will be more critical depending on who you are as an investor and how you react to market volatility. However, if you are locking your investment sandscape to a long-term horizon, comparing the fundamental indicator across CbdMD's competition over several years is one of the best ways to analyze its investment potential.| Better Than Average | Worse Than Peers | View Performance Chart |
CbdMD Competition Performance Charts
Five steps to successful analysis of CbdMD Competition
CbdMD's competitive analysis is the process of researching and evaluating its competitive landscape. It provides an understanding of the strengths, weaknesses, opportunities, and threats (SWOT) faced by cbdMD Inc in relation to its competition. CbdMD's competition analysis typically involves several steps, including:- Identifying the key players in the market: This involves identifying the major competitors of CbdMD in the market, both direct and indirect, as well as new entrants and disruptive technologies.
- Assessing the strengths and weaknesses of each competitor: This involves evaluating each competitor's strengths and weaknesses in areas such as product offerings, market share, brand recognition, financial performance, and distribution channels.
- Understanding the competitive environment: This involves evaluating the regulatory environment, economic conditions, and other factors that may impact CbdMD's competitive landscape.
- Identifying opportunities and threats: This involves using the information gathered during the analysis to identify opportunities and threats to cbdMD Inc, and developing a strategy to address them.
- Evaluating the competitive landscape: This involves understanding the competitive dynamics of the market, such as pricing, marketing, and distribution strategies, as well as analyzing the competitive advantage of each competitor.
Complement your CbdMD position
In addition to having CbdMD in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Disruptive Technologies Thematic Idea Now
Disruptive Technologies
New or established technology companies and funds across multiple sectors that are involved in development or marketing of products or services that experience disruptive trends and that are at the forefront of discussions on Wall Street. The Disruptive Technologies theme has 64 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Disruptive Technologies Theme or any other thematic opportunities.
| View All Next | Launch |
Check out CbdMD Correlation with its peers. You can also try the Insider Screener module to find insiders across different sectors to evaluate their impact on performance.
Will Pharmaceuticals sector continue expanding? Could CbdMD diversify its offerings? Factors like these will boost the valuation of CbdMD. Anticipated expansion of CbdMD directly elevates investor willingness to pay premium valuations. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every CbdMD data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
Earnings Share 0.51 | Revenue Per Share | Quarterly Revenue Growth (0.11) | Return On Assets | Return On Equity |
cbdMD Inc's market price often diverges from its book value, the accounting figure shown on CbdMD's balance sheet. Smart investors calculate CbdMD's intrinsic value - its true economic worth - which may differ significantly from both market price and book value. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. Since CbdMD's trading price responds to investor sentiment, macroeconomic conditions, and market psychology, it can swing far from fundamental value.
Please note, there is a significant difference between CbdMD's value and its price as these two are different measures arrived at by different means. Investors typically determine if CbdMD is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, CbdMD's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.